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Summary
Background Studies have suggested that asthma in obese individuals differs from the
classic asthma phenotype, presenting as a disease that is more difficult to control.
Objective The objective of the present study was to determine whether obesity, age or a
combination of the two are associated with worse spirometry parameters in patients with
asthma.
Methods This was an observational cross-sectional study involving patients over 18 years
of age who had been diagnosed with asthma (allergic or nonallergic). We evaluated the
results of their spirometric tests. The patients were classified in accordance with two crite-
ria: body mass index (BMI) and age. Based on their BMIs, the patients were divided into
three groups: normal weight, overweight and obese. Patients were also separated into two
categories by age: 18–59 years of age; and  60 years of age.
Results We evaluated 451 patients with asthma and their spirometry tests. In the present
study, the pulmonary function parameters were negatively correlated with BMI and age
(P < 0.05). We found that there was a statistically significant correlation between spiro-
metric values and BMI among patients 18–59 years of age (P < 0.001), however, among
patients over 60, we did not observe this negative association.
Conclusions and Clinical Relevance The spirometric values decreased significantly in pro-
portion to the increase of BMI and age in patients with asthma, especially among young
adults. There was no negative correlation between BMI and FEV1 in the group  60 years
of age, suggesting that perhaps the time of disease is a major factor in the loss of lung
function than weight gain in the elderly.
Submitted 19 August 2011; revised 11 November 2011; accepted 14 December 2011
Introduction
The world-wide prevalence of asthma is high, as is that
of obesity, and many studies suggest that the two con-
ditions are correlated [1–4]. There is epidemiological
evidence that obesity is a risk factor for developing
asthma, and the association between obesity and asthma
might be mediated by common genetic, environmental
and psychosocial factors [2–4]. According to a meta-
analysis conducted in 2007, the incidence of asthma can
be as much as 50% higher in individuals who are over-
weight or obese than in those of normal weight [5].
Both obesity and asthma have an enormous impact
on public health and their prevalence is on the rise. It
is estimated that 45% of adults in Brazil and 65% of
adults in the USA are overweight or obese, and asthma
affects approximately 10% of individuals worldwide
[6–9]. In addition, the prevalence of overweight tends
to increase with age, and this increase is accelerated
after the age of 45 years [9]. Although the exact nature
of the correlation between asthma and obesity has yet
to be fully clarified, some epidemiological data suggest
that obesity can precede asthma and can increase its
severity, as well as decrease the effectiveness of the
drugs that are commonly used in asthma treatment
[6, 10, 11].
In asthma, patients who are obese, weight loss can
lead to clinical and physiological improvement in rela-
tion to the symptoms of asthma [1, 12]. Certain factors
complicate the diagnosis of asthma in obese individuals
[3]. Even in individuals without asthma, obesity has
numerous consequences for respiratory physiology,
including decreased lung compliance (caused by
reduced lung volume and chest wall restriction).
Obesity also increases airway resistance, increases
oxygen consumption during respiratory effort, causes
respiratory muscle dysfunction and creates an imbal-
ance in the ventilation/perfusion ratio. Forced expira-
tory volume in one-second (FEV1), forced vital capacity
(FVC) and, especially, expiratory reserve volume (ERV)
are reduced [6, 13]. In addition, obesity contributes to
comorbidities, such as gastroesophageal reflux disease
and sleep apnoea, both of which can mimic asthma or
can coexist with it and make it difficult to control [5].
It has been speculated that the association between
asthma and obesity is attributable in part to the effect
that excess weight has on respiratory physiology, as well
as to the increased production of inflammatory mediators
seen in obese individuals. Although obesity and impaired
pulmonary function both correlate positively with age,
body mass index (BMI) has been shown to have an age-
independent effect on pulmonary function [9, 12].
Many studies have demonstrated that obesity leads to
a systemic inflammatory state. Adipocytes can release
proinflammatory hormones, which might increase the
prevalence and severity of asthma in the obese popula-
tion [11, 14]. Therefore, BMI is a variable that should
be taken into consideration in patients with asthma [7].
Studies have suggested that asthma in obese individuals
differs from the classic asthma phenotype, presenting as
a disease that is not only more difficult to control but
also one that does not respond as well to inhaled corti-
costeroids [11, 15].
The objective of the present study was to determine
whether obesity, age or a combination of the two are
associated with worse spirometry parameters in patients
with asthma, particularly FEV1, which is one of the
criteria for classification of asthma severity and its con-
trol [2].
Methods
Sample
This was an observational and cross-sectional study
involving patients over 18 years of age who had been
diagnosed with asthma (allergic or nonallergic). Patients
were recruited from the Asthma Outpatient Clinic of the
Department of Clinical Immunology and Allergy of Sa˜o
Paulo University, located in the city of Sa˜o Paulo, Bra-
zil. All patients were under clinical treatment and out-
of-attack of asthma. Patients with persistent asthma
were using inhaled corticosteroids and those with inter-
mittent asthma, were using nasal steroids daily.
We evaluated the results of spirometric tests con-
ducted between February of 2009 and December of
2009. All patients met the criteria for a diagnosis of
asthma as set forth in the Global Initiative for Asthma
guidelines [2]. All of them were over 18 years of age,
with technically adequate spirometry. Patients with
other lung diseases were excluded.
Patients were classified in accordance with two crite-
ria: BMI and age. Based on their BMIs, the patients
were divided into three groups: normal weight (BMI: 18
–24.9 kg/m2); overweight (BMI: 25–29.9 kg/m2); and
obese (BMI: 30 kg/m2). Waist–hip ratio (i.e. the waist
circumference divided by the hip circumference) was
suggested as an additional measure of body fat distri-
bution. BMI has traditionally been the chosen indicator
by which to measure body size and composition, and to
diagnose underweight and overweight [16]. Although
alternative measures that reflect abdominal adiposity,
such as waist circumference, waist–hip ratio and waist–
height ratio, have been suggested as being superior to
BMI in predicting cardiovascular disease risk, we have
chosen BMI because it is an index used frequently in
studies of change in lung function and obesity [17].
Index measuring manoeuvres which are more practical
and reliable than the values of the formula are pre-
sented and to be checked before each spirometry.
Patients were also separated into two categories by age:
18–59 years of age; and  60 years of age.
Spirometry
All spirometric tests were performed between 7:00 and
9:00 am, by the same technician, with a Koko spirome-
ter (PDS Instrumentation, Louisville, CO, USA), which
provides flow-volume curves and volume-time curves.
Bronchodilator treatment was discontinued 12 h before
the test, whereas other medications were not. The tests
measured FVC, flow-volume curves and volume-time
curves. The spirometric tests provided values for FEV1
and FVC, from which the FEV1/FVC ratio was calculated.
The techniques used for performing spirometry and
interpreting the results were those recommended by the
2005 American Thoracic Society consensus and the 2005
European Respiratory Society consensus [18, 19]. How-
ever, the reference values used were those established in
the Brazilian Spirometry Guidelines set forth at the Sec-
ond Brazilian Consensus on Spirometry in 2002 [20]. The
tests were repeated 15 min after the inhalation of 400 lg
of albuterol via a metered-dose inhaler with a spacer.
Bronchodilator response was defined as an increase
(over baseline) of at least 12% and 200 mL in FEV1 or
FVC. The FEV1 values were categorized based on the
percentage of the predicted value (FEV1%): normal
(80); mild defect (60–79); moderate defect (41–59);
and severe defect (40).
Statistical analysis
To compare the groups with regard to BMI, age and
spirometric values (FEV1% and FVC%), we used one
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way analysis of variance (ANOVA) and the multiple com-
parison procedures (Student–Newman–Keuls method).
We used Pearson’s chi-square test to compare categori-
cal data, which are expressed as absolute frequency (n)
and relative frequency (%) of FEV1 and FVC values. The
level of significance was set at P < 0.05.
Results
We evaluated 451 patients and 451 corresponding sets
of spirometry results. Patient ages ranged from 18 to
86 years (mean age: 49.2 ± 15.7 years), and 351 (78%)
of them were women. Of the 451 patients evaluated,
153 (33.9%) were classified as normal weight, 153
(33.9%) as overweight and 145 (32.2%) as obese. Of the
145 obese patients, 123 (84.8%) were female patients.
Mean age was higher in the obese group than that in
the overweight and normal-weight groups (51.6 years
vs. 50.4 years and 45.8 years). Table 1 shows the mean
BMI, demographic characteristics and spirometric data
for each group.
In the present study, the pulmonary function parame-
ters were negatively correlated with BMI (P < 0.05) and
age (P < 0.05), as can be seen in Fig. 1. The spirometry
results were evaluated in terms of the FEV1%. Almost
half the patients (48.3%) presented with an FEV1%  80,
and only 2.0% presented with an FEV1%  40 (Fig. 2).
In the FEV1%  80 group, there were more non-
obese individuals than obese, representing 73.9% of the
non-obese group (Table 2), with statistically significant
difference (P = 0.012, x2). The highest proportion of
patients with abnormal FEV1% values was seen in the
obese group, 60.7% of these patients presenting with an
FEV1% < 80 (Fig. 2).
Among the overweight patients, the pattern of distri-
bution of FEV1 values was similar to that observed
among the normal-weight patients, although the pro-
portion of patients presenting with a baseline FEV1%
 80 was lower (51% of overweight and 54.2% of nor-
mal-weight patients). In the obese group, only 57 indi-
viduals (39.3%) and in non-obese (normal weight plus
overweight) 161 patients (52.6%) had FEV1%  80
(P = 0.012), as shown in Fig. 2. Moreover, there was a
loss in volume FEV1 (L) of 17.7% when we compared
the obese patients to those with normal weight
(Table 1). The decrease in the number of patients is
directly proportional to the fall in FEV1 in non-obese
(normal weight plus overweight) patients, which did not
occur in the obese group, where only 39.3% had FEV1
 80%. In addition, groups of FEV1 between 40% and
79% have a predominance of obese patients compared
to those non-obese patients.
The FVC analysis showed that about 80% of normal
or overweight patients had levels above 80%, and
among obese patients 73% had FVC%  80 (P = 0.088,
x2). Analysing the mean FVC% among the three groups,
we found a decrease in FVC% in the obese group com-
pared to the other two groups (Fig. 3). We found that
only 27% of obese patients had FVC% < 80, although
60.7% of the obese group had FEV1% < 80. There was
a loss in volume of FVC of 14% in obese compared to
normal-weight patients (Table 1).
The patients were also separated into two categories
by age, 18–59 years of age; and  60 years of age.
Table 3 shows the mean BMI and spirometric data for
each group, stratified by age (18–59 years of age
and  60 years of age). Of the 451 patients, 328
(72.7%) were 18–59 years of age, and 123 (27.3%)
were  60 years of age.
The mean age of patients over 60 was
68.1 ± 6.6 years. In the group of patients 18–59 years
of age, BMI was found to correlate positively with age
and negatively with FEV1, similar to what was observed
for the sample as a whole (Figs 4a and c).
Although the FEV1 and FVC values were lower in the
group of patients  60 years of age, there was no corre-
lation between FEV1(%) values and BMI in this age
bracket (P < 0.746), as shown in Fig. 4b. This figure also
shows the negative correlation between FEV1 and age
only in the group of patients 18–59 years of age.
The spirometric patterns differed between the two age
brackets. Figure 5 shows the FEV1% values for the
normal-weight group only, comparing the two age
brackets. Within the normal-weight group, 64.6% of 18
–59 years of age patients had FEV1%  80, whereas
75% of elderly patients (60 years of age) had FEV1%
< 80, showing that the number of abnormal spirometry
results was significantly higher among the patients
 60 years of age (P = 0.015, x2). Among the over-
weight patients, the proportion presenting with FEV1%
Table 1. Patients distribution according to BMI
Age (years) BMI (kg/m2) FVC (L) FVC (%) FEV1 (L) FEV1 (%) Index (FEV1/FVC) Female (%)
Normal weight 45,8 ± 17,8 22,7 ± 1,71 3,17 ± 0,98 93,0 ± 16,7 2,31 ± 0,87 81,2 ± 19,3 0,72 ± 0,1 70,8
Overweight 50,4 ± 14,6 27,3 ± 1,33 2,95 ± 0,83 91,2 ± 15,1 2,11 ± 0,67 79,9 ± 17,1 0,71 ± 0,1 77,3
Obese 51,6 ± 13,6 34,0 ± 3,73 2,71 ± 0,80 86,8 ± 15,0 1,90 ± 0,62 74,9 ± 17,7 0,70 ± 0,1 84,8
Results: mean ± SD.
BMI, body mass index; FEV1, Forced expiratory volume in one-second; FVC, forced vital capacity.
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values between 41 and 59 was 9.6% for those
18–59 years of age and 17.9% for those  60 years of
age (data not shown).
Discussion
In the present study, we found that there was a nega-
tive correlation between FEV1 and BMI, and the mean
FEV1% being 17.4% lower among the obese patients
than among the normal-weight patients. The proportion
of female patients was higher in the obese groups than
that in the other groups, as was the mean age. Our
study found a high prevalence of asthmatic women
(77.8%), especially those with more severe asthma
(84.8%). The more severe asthma, by evaluating spiro-
metric values such as FEV1, was also more prevalent in
the group with BMI  30. According to WHO, obesity
is more prevalent in women than in men, a ratio of
3 : 2 [16]. In addition, asthma is more prevalent and
more severe in women as demonstrated in several stud-
ies [21–23]. In this study, BMI correlated positively with
age and with being of the female gender. FEV1 and
FVC values were lower among asthma patients who
were overweight or obese, especially among the latter,
than among those of normal weight. This finding is in
accordance with data in the literature [2, 13, 24].
When the spirometric values for asthma patients were
evaluated by BMI and age bracket, a statistically signif-
icant correlation between spirometric values and BMI
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Fig. 1. Correlation between FEV1 (%) pre-bronchodilator and BMI
(kg/m2) or age (years). (a) Negative correlation between FEV1 and
BMI (Pearson correlation, P = 0.001); (b) negative correlation between
FEV1 and age (Pearson correlation, P < 0.0001).
Table 2. Patients distribution according to FEV1% and weight
FEV1% Non-obese (n/%) Obese (n/%)
80% 161/73.9 57/26.1
60–79% 105/63.5 60/36.5
41–59% 34/57.6 25/42.4
40% 6/66.7 3/33.3
Non-obese: normal weight plus overweight patients.
Statistical analysis: P = 0.012, x2.
FEV1, Forced expiratory volume in one-second.
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Fig. 3. Mean FVC (%) pre-bronchodilator values according to BMI
(kg/m2). Statistical analysis (Student–Newman–Keuls method):
*P = 0.002; §P = 0.313; #P = 0.016.
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was found only for the patients 18–59 years of age. In
this group, FEV1% was found to be lower among the
patients who were obese than among those who
were not (Fig. 1a). Overall, FEV1% was lower among
the patients  60 years of age than among those
18–59 years of age. Only 25% of the normal-weight
elderly patients presented with an FEV1%80,
compared with 65% of those 18–59 years of age
(Fig. 5). The negative correlation between FEV1% and
age might have a greater impact than that between
FEV1% and BMI in the group of patients  60 years of
age as demonstrated in Fig. 1b.
Pulmonary function peaks in early adulthood [13].
During that phase of life, the factors affecting
pulmonary function include gender and ethnicity, as
Table 3. Spirometric values according to BMI and age group
Age group BMI age (mean) BMI (kg/m2) FVC (L) FVC% FEV1 (L) FEV1% FEV1/FVC
<60 normal weight 37,5 22,7 3,44 96,1 2,58 84,7 0,75
overweight 44,2 27,3 3,16 92,5 2,28 80,3 0,72
obese 45,1 34 2,91 88,2 2,03 74,5 0,7
60 normal weight 69,4 22,8 2,4 84,3 1,55 71,5 0,64
overweight 68,4 27,2 2,34 87,4 1,62 78,8 0,69
obese 66,6 34 2,27 83,3 1,59 75,8 0,69
BMI, body mass index; FEV1, Forced expiratory volume in one-second; FVC, forced vital capacity.
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Fig. 4. Correlation between FEV1 (%) pre-bronchodilator and BMI (kg/m
2) or age (years), according to age group (< 60 years and  60 years). (a)
Negative correlation between FEV1 and BMI for patients < 60 years of age (Pearson correlation, P < 0.0001); (b) no correlation between FEV1 and
BMI for patients  60 years of age (Pearson correlation, P = 0.746); (c) negative correlation between FEV1 and age for patients < 60 years of age
(Pearson correlation, P < 0.001); (d) no correlation between FEV1 and age for patients  60 years of age (Pearson correlation, P = 0.709).
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vs. abnormal (FEV1% < 80) spirometric values: P = 0.015, x
2.
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well as exposure to cigarette smoke and particulate
matter. In the later stages of life, the level of pulmonary
function is determined by early lung development and
the level of function achieved in adulthood, as well as
by the lifetime exposure to cigarette smoke, pollution
and occupational contaminants. In addition, there is a
decline in pulmonary function related to the ageing
process itself [13].
In this study, we observed that there was loss of lung
volume with increasing body weight. The FEV1/FVC
ratio remained at a similar level among the three BMI
groups, suggesting that with the increase in BMI there
was a decrease of FEV1 (L) as a consequence of reduced
FVC. However, when we evaluated the volume (L) drop
in both age groups, we found that, in 18–59 years of
age obese patients, the fall in FEV1 was 21.3% and that
in FVC was 15.4%, which suggests obstructive ventila-
tory defect (Table 3).
So even with the likely loss of FEV1 as a result of
FVC decline in obese patients, the decrease in FEV1 was
greater than that of FVC. Nevertheless, in elderly
patients, we did not find this fall in FEV1/FVC
ratio, but these values were lower than those of patients
18–59 years of age, suggesting greater influence of
disease duration. Holguin et al. recently demonstrated
that increase in BMI was positively associated with
asthma severity, especially in those with early asthma
(<12 years of age) [25].
Other authors have shown a correlation between pul-
monary function and BMI [13]. A cross-sectional study
conducted in 2006 employed plethysmography to eval-
uate the effects of BMI on the lung volumes of 373
patients with asthma [24]. It was shown that the lung
volumes, principally functional residual capacity (FRC)
and ERV, correlated negatively with BMI. On average,
every 1 kg/m2 increase in the BMI resulted in a 0.5%
decrease in vital capacity, total lung capacity and resid-
ual volume. The authors found that, BMI correlated
most significantly with FRC and ERV [24].
Obesity also increases airway responsiveness in
otherwise healthy humans [26]. Various cross-sectional
and longitudinal studies have demonstrated age-related
changes in body composition. As age advances, individ-
uals tend to become more obese, with an increase in
the amount of visceral fat and a decrease in skeletal
muscle mass [27–29].
Pulmonary function also decreases with age [30]. The
physiological ageing of the respiratory system is associ-
ated with changes in chest wall and lung compliance,
as well as with air trapping, increased FRC and
increased respiratory effort [30]. Expiratory flow rates
also decrease with age. Respiratory muscle function is
impaired as a result of geometric changes in the chest
wall and depends on nutritional status, peripheral mus-
cle mass and the cardiac index [30]. Therefore, body
composition and body fat distribution are associated
with reduced pulmonary function in elderly individuals
[27]. These age-related changes are clinically relevant
because reduced pulmonary function is associated with
an increase in the mortality rate. In elderly individuals,
there is a central pattern of fat distribution, which is
negatively correlated with pulmonary function [27].
This pattern of fat distribution might be related to
changes in pulmonary function through various mecha-
nisms, such as the mechanical effect that excess fat has
on the diaphragm (hindering its descent to the abdomi-
nal cavity) and on the chest wall (resulting in changes
in lung compliance, respiratory effort and lung elastic
recoil). Since total adiposity and visceral fat tend to
increase with age, these changes contribute to the
decline in pulmonary function observed in elderly indi-
viduals. It is particularly important to consider weight
loss treatment in to improve pulmonary function in
obese individuals [28].
One study demonstrated that obese patients with
asthma benefit from weight loss, which results in
increased pulmonary volumes and improved respiratory
mechanics [31]. Weight loss not only reduces airway
obstruction and the variability in peak expiratory flow,
but also improves asthma symptoms [31]. There is less
evidence that weight loss can improve bronchial hyp-
erreactivity [5, 12].
Our results indicate that FEV1 and FVC decrease sig-
nificantly in proportion to increases in BMI and age. We
found that there was a statistically significant correla-
tion between spirometric values and BMI among patients
18–59 years of age. The group of patients  60 years of
age had smaller lung volumes than the other group.
However, there was not a negative correlation between
BMI and FEV1 in this age group, suggesting that perhaps
the time of disease is a major factor in the loss of lung
function than weight gain in the elderly.
Conclusions
The spirometric values decreased significantly in pro-
portion to the increase of BMI and age in patients with
asthma. These results are repeated only in the group
< 60 years of age. This negative association was not
observed in the elderly group. These results suggest that
lower spirometric values observed in older patients,
without correlation with obesity, may be a consequence
of disease duration.
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